August 29, 2019 | August was full of exciting news in the clinical trial and healthcare community, including partnerships, products, and promotions from WCG, Cenduit, Evidera, and more.

WCG's Clinical Services Division introduced Velos eResearch eXpress, an out-of-the-box, cloud-based solution that enables clinical research sites to centralize and manage their research activities on a single, automated technology platform. Velos eResearch eXpress provides the first Site CTMS designed for smaller institutions and independent sites which do not have access to the budget, resources and scale required to implement the costly, large, and complex systems provided by other CTMS providers. Developed by WCG Velos, the trusted provider of clinical trial management solutions (CTMS) that increase the productivity and efficiency of clinical research, Velos eResearch eXpress is a fully-scalable solution that supports the sustainable advancement and growth of independent and emerging clinical research sites by making the execution of their research operations more transparent, organized and more profitable. Velos eResearch eXpress is a pre-configured version of the industry-leading Velos eResearch solution, an enterprise platform that is trusted by the most prominent research sites in the US. Embedded with research best practices, as well as standards-based libraries and templates, Velos eResearch eXpress hard-wires accuracy and compliance in research management. The solution also increases efficiency by consolidating all aspects of research management on a single automated platform: financial management, patient management, study management, calendaring, and reporting. Press release

Evidera has entered into an exclusive collaboration agreement with Clinical Study Support (CSS), a subsidiary of Shin Nippon Biomedical Laboratories, extending both organizations' capabilities to deliver more robust consulting and analytical capabilities and creating a more complete geographic customer solution for clinical, real-world and patient-centered research.  Together, Evidera and CSS will leverage their combined expertise, including Japan-based multilingual experts, to provide research services to global or Japan-based clients undertaking studies that include a Japanese component. Such research services include the design and implementation of real-world studies, epidemiological studies, qualitative and quantitative patient-centered research, clinical outcome assessment development and validation, patient recruitment for prospective studies, health economics modeling, and market access and health technology assessment consulting services. The companies also are committed to the joint development of direct-to-electronic medical record (EMR) and EMR-enabled observational studies in Japan. Press release

Cenduit has announced a Bangalore expansion, as the latest development across the organization's global operations in Asia Pacific (APAC), North America, and Europe. The move in India solidifies Cenduit's positioning as the global innovator of IRT (Interactive Response Technology) systems that deliver quantifiable improvements in clinical trial safety, compliance and costs; as well as continuous commitment to delivering operational excellence for customers across APAC. Cenduit CEO Sam Osman commented, "Cenduit's strong growth illustrates the biopharma industry's increasing reliance on our ability to deliver digitized, integrated technology systems that create greater scientific and economic efficiencies for patient outcomes. We're gratified at the industry's response to Cenduit's dedication to quality-first systems and services that meet the needs of this growing market. We look forward to continuing to work with our channel partners worldwide as we sustain robust market expansion." Press release

Signant Health has appointed Anthony Todd Everhart to the Signant Health Science and Medicine Team as Clinical Vice President, Internal Medicine, reporting to the Chief Medical Officer, Dr. David Daniel. As a technology company, Signant is unique in its commitment to data quality, consistency and integrity due to its internal team of renowned scientists, experienced clinicians and analytics experts. Signant provides customers with an extra layer of confidence through proactive and near real-time monitoring and assessments of incoming clinical data. With its eCOA and Endpoint Quality solutions, Signant identifies risks and provides actionable remediation recommendations where appropriate to avoid and correct potential issues before they become threats that can negatively impact the trial. Dr. Everhart is Board-certified in Internal Medicine and a Fellow of the American College of Physicians with over 23 years of experience in the practice of medicine and over 12 years of experience in clinical development. Prior to joining Signant, Dr. Everhart held positions of Vice President, Medical Affairs and Vice President, Medical Informatics at Chiltern and Covance, and most recently consulted independently in the areas of Medical Monitoring, Medical Data Review, and Physician Adoption of Technology. He has worked in all phases of clinical development in numerous therapeutic areas including Allergy & Immunology, Cardiovascular, Hematology & Oncology, Infectious Disease & HIV, Neurology, Ophthalmology, Psychiatry, Respiratory, and Rheumatology. With Signant Health, Dr. Everhart will help accelerate the application of Signant's intelligent eCOA, rater training, predictive analytics and other data quality monitoring products outside of CNS disorders. Press release

Biological Specialty Company (BSC) announced the introduction of a series of enhancements to the donor experience at its centers in Colmar, Allentown and Reading, PA. BSC specializes in collecting blood, plasma, serum, white cells, red cells, and other biofluids from consented donors. "We greatly value our donors and their contributions of blood products and biospecimens to further medical research," said BioIVT VP of Donor Center Operations Jeff Widdoss, in a press release. "We wanted to show our appreciation in tangible ways, such as by providing upgraded refreshments, improved compensation, additional entertainment options during donations, and a dedicated donor services team." Press release

Q-State Biosciences and 2bPrecise will partner to build robust clinical-genomic datasets enabling healthcare providers to better leverage precision medicine when treating patients with genetic conditions. The collaboration will facilitate the advance of novel insights that health systems can incorporate to improve clinical practice and that pharmaceutical companies can use in the development of new therapies. The partnership – backed by 2bPrecise parent company Allscripts Healthcare Solutions – will combine 2bPrecise’s cloud-based, EHR-independent platform that brings genomic data into the clinical workflow with Q-State’s whole-genome and whole-exome sequencing, transcriptomics and leading functional phenotyping capabilities. The collaboration will benefit patients and care organizations by supporting improved diagnostic yields and patient outcomes, and by providing clinical tools to help match patients with precise therapies based on their health attributes and genetic profile. Likewise, it will help pharmaceutical firms accelerate therapeutic discovery through the identification of novel disease targets, stratification of patient populations and expedited clinical-trial recruitment paths. Press release